查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853864

新型药物递送系统市场（依给药途径、技术、应用、产品类型及最终用户划分）－2025-2032年全球预测

Novel Drug Delivery Systems Market by Route Of Administration, Technology, Application, Product Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，新型药物输送系统市场规模将达到 311.3 亿美元，年复合成长率为 9.55%。

主要市场统计数据
基准年 2024 150亿美元
预计年份：2025年 164亿美元
预测年份：2032年 311.3亿美元
复合年增长率 (%) 9.55%

全面审视跨学科创新和以患者为中心的设计如何重新定义新型药物输送平台的目的和机会

随着分子创新与先进材料科学和以患者为中心的护理模式的融合，药物递送格局正在发生根本性的重塑。新型药物递送系统涵盖多种平台，从吸入装置和注射剂到经皮吸收贴片以及尖端的微奈米载体，每一种都旨在提高治疗指数、黏附性和靶向生物分布。本执行摘要概述了影响生物製药、医疗技术和特种医疗器材製造商研发重点和投资策略的关键技术、监管和商业性曲折点。

在各个治疗领域，研发人员正将给药途径视为药物价值不可或缺的一部分，而非次要因素。这种转变推动了产品开发生命週期的整合，製剂科学家、医疗设备工程师和临床团队共同设计解决方案，以满足复杂的安全性、稳定性和易用性要求。此外，对门诊和居家给药的日益重视也正在改变产品规格和供应链的考量。因此，能够将科学创新与实际应用和医保报销管道相结合的相关人员，将在商业可行性和患者接受度方面拥有关键优势。

精准标靶化、数位整合和策略伙伴关係如何重塑先进医学的临床价值创造和商业化

药物递送领域正在发生多项变革性转变，加速其发展进程，并重新定义新治疗方法的成功标准。首先，奈米颗粒、脂质体系统和植入式装置实现的精准标靶治疗已从概念验证发展到实际临床应用阶段，能够在病灶部位实现更高的治疗浓度，同时降低全身暴露。这项技术的成熟，加上监管机构组合药物和新型辅料日益增长的认可，使得更具雄心的製剂和整合式装置解决方案成为可能。

同时，数位医疗的融合正在改变人们对依从性监测和个人化给药的预期。智慧植入、连网输液帮浦和整合感测器的贴片正在将给药系统从被动载体转变为医疗照护管道中的积极参与者。製药公司和专业医疗器材公司之间的策略联盟日益普遍，这反映出人们认识到，要克服复杂的研发、生产和生命週期管理挑战，互补的专业知识必不可少。总而言之，这些动态正在形成一个格局：跨职能协作、监管灵活性和供应链韧性将决定哪些创新能带来有意义的临床和商业性成果。

2025年美国关税调整的商业和战略影响、采购模式的重塑、製造业在地化以及供应链的韧性

2025年美国关税政策为生命科学供应链带来了微妙的营运和策略压力，对零件采购、製造地选择和成本结构的影响各不相同。针对特定原料和设备零件征收的关税增加了某些聚合物、特殊脂质和用于互联连网型设备的电子子系统的进口成本。这项变化促使先前依赖全球化、成本优化筹资策略的製造商重新评估其营运模式。

为因应关税波动，许多公司加快了关键供应链的在地化进程，或建立了双重采购安排，以降低关税波动带来的风险。提高采购和生产的透明度成为当务之急，同时增加对供应链分析的投资，以建立产品系列组合的关税敏感性模型。重要的是，这些调整不仅限于短期成本管理；生产在地化、替代材料认证和设备结构重新设计等决策都会影响监理申报策略和产品上市时间。那些积极将关税情境规划纳入商业化蓝图的公司，能够在确保利润率和供应连续性的同时，维持研发进度。

将给药途径、实行技术、治疗用途、产品类型和最终用户管道连结起来的可操作细分情报，能够实现精准的策略定位。

细分市场层面的动态揭示了不同的机会和技术限制，这些都为研发优先排序和商业化规划提供了基础。就给药途径而言，吸入平台（包括干粉吸入器和雾化器）正在进行重新开发，以支持生技药品和局部治疗；而注射剂型（包括肌肉注射、静脉注射和皮下注射）仍然是全身生技药品和长效持续性注射剂的核心。鼻腔输注和喷雾给药是快速中枢神经系统和黏膜免疫策略的理想途径，而口服胶囊、液体和药片等给药方式则持续优化，以提高药物稳定性和患者依从性。经皮给药（透过凝胶和贴片实现）越来越适用于需要长期、持续给药以及需要稳定血浆浓度的治疗。

植入，无论可生物降解或不可生物降解，均支持长期局部治疗并减少给药频率。涂层、可溶解、中空和固体微针可提供微创给药方式，方便患者自行给药；而诸如树状聚合物、各类脂质体、聚合物奈米颗粒和固体脂质奈米颗粒等奈米颗粒平台则可实现标靶递送和控释。其应用包括：利用支架和经导管装置进行介入心臟病学；专注于糖尿病管理和荷尔蒙疗法的内分泌解决方案；用于抗生素、抗病毒药物和疫苗的感染疾病递送渠道；用于治疗中枢和周围神经系统疾病的神经病学方法；用于化疗、免疫疗法和标靶药物的肿瘤递送系统；以及从滴眼液到眼内植入的眼科解决方案。

具有优异黏附性的可生物降解和不可生物降解的缓释注射剂、冠状动脉和周边药物释放型支架以及植入式帮浦（例如输液帮浦和渗透帮浦）都需要持久耐用的电源和控制解决方案。标准脂质体和隐形脂质体配方会影响药物动力学和免疫抗原性。可溶解和固态微针贴片提供了独特的生产规模化途径。最后，对门诊、诊所、居家医疗、医院和药房等终端用户进行细分，可以确定分销模式、培训要求和报销环节。整合这些细分讯息，可以实现细緻的产品设计和上市顺序，从而使技术可行性与临床应用管道相匹配。

美洲、欧洲、中东和非洲以及亚太地区的监管、报销和生产环境将如何影响发展重点和市场进入顺序？

区域动态影响新型给药系统的研发、生产和商业化的优先事项。在美洲，生技药品和植入式技术的创新丛集与先进的医保报销体系并存，这可能加速其应用；然而，供应炼和关税方面的考量需要对区域生产和监管进行调整。欧洲、中东和非洲的情况则呈现差异性。虽然成熟的监管管道和集中采购可能有利于欧洲部分市场中先进医疗设备和组合产品的推广，但该地区的新兴市场可能更倾向于成本效益高、易于操作的解决方案和分散式医疗模式。亚太地区拥有庞大的病患群体、不断扩展的临床试验能力和快速的工业规模化生产能力，这为其提供了多元化的商业机会；然而，进入亚太市场需要仔细了解各国具体的监管细则和当地的生产预期。

这些区域特征会影响合作伙伴的选择、临床开发策略和商业化顺序。例如，企业可能会优先在报销政策有利且拥有强大专业管道的市场进行探索性上市，然后再扩展到价格敏感或采购流程决定了其价值提案的地区。同样，监管沟通策略也应反映医疗器材和生技药品管治的区域差异，以便儘早进行对话，评估可行性并优化管道。在製定全球愿景的同时兼顾区域执行计划，对于在应对营运复杂性的同时获得市场认可至关重要。

透过整合技术堆迭、策略合作、实际应用案例和对卓越製造的专注，实现竞争优势差异化。

新型药物递送系统领域的竞争格局呈现出成熟製药公司、器材专家和敏捷创新者并存的局面。业界领导者凭藉垂直整合的能力脱颖而出，这些能力涵盖製剂科学、器械工程和生产规模化，从而加速从概念到临床的转化。从许可和共同开发契约到股权投资，策略联盟已成为获取互补能力的常用途径，尤其是在奈米颗粒工程、微针製造和数位健康整合等领域。

智慧财产权仍然是竞争优势的核心支柱，强大的核心材料、给药机制和设备介面专利系列可以构成显着的进入障碍。然而，成功的商业化越来越依赖产生真实世界证据以确立差异化价值、以使用者为中心的设计检验以及与支付方的互动。投资于完善的上市后监测、依从性分析和临床结果研究的公司将更有能力捍卫定价并扩大适应症。合作伙伴和收购方更青睐那些已证明其能够规模化生产复杂生技药品、维持无菌状态并高效推进组合药物申请的公司。

为生命科学产业领导者提供切实可行的、优先排序的策略行动，以协调研发、供应链韧性和商业性证据的产生，以实现永续应用。

行业领导者应采取一系列优先行动，将技术前景转化为可持续的商业性成果。首先，在药物研发早期阶段就应纳入药物发行策略，与临床和监管团队共同设计製剂和装置。其次，应实现供应链多元化，寻找替代材料和供应商以降低关税和地缘政治风险，并在关键组件采购方面建立冗余机制。第三，应投资于复杂製剂（包括脂质体和奈米颗粒系统）的中试生产和可扩展製程验证，以缩短产品进入关键测试阶段所需的规模生产时间。

此外，我们建立策略伙伴关係，以充分利用互补能力，例如微针製造、植入式设备工程和数位化依从性技术，并建立平衡风险和效益的交易结构。我们透过设计以结果为导向的证据项目来强化我们的价值主张，这些项目将临床终点与支付方的要求和最终用户获益（例如减少门诊就诊次数和提高依从性）相结合。最后，我们优先考虑人为因素和培训项目，以确保新型设备和给药途径对临床医生和患者都易于理解和使用，从而平滑门诊和居家医疗环境中的推广应用曲线。这种综合方法提高了临床成功和商业性推广的可能性，同时确保了利润率并促进了患者的就医。

一项可复製的混合方法研究途径将严谨的二手研究与专家访谈相结合，以检验技术准备和商业性动态。

本报告基于结构化的调查方法，结合了多来源文献的二手资料分析和有针对性的一手调查，从而确保研究结果的稳健性、实用性和可重复性。二手资料分析包括对同行评审文献、监管指导文件、专利申请和技术白皮书的仔细审查，以梳理技术趋势、监管先例和材料科学领域的进展。这些二手资料的分析结果促成了基础分类系统的建立，该系统用于对给药途径、实行技术、治疗用途、产品类型和终端用户管道进行细分。

初步研究包括对跨职能相关人员进行深入访谈，这些利害关係人包括製剂科学家、器材工程师、法规事务专家、临床研究人员、生产负责人和商业高阶主管。这些访谈验证了技术可行性评估，突显了实际应用中的障碍，并揭示了区域采购和报销动态。定量检验透过与二级资讯来源和技术成熟度指标交叉比对进行。最后，内部专家将证据综合成情境分析和策略建议，并透过反覆审查来消除潜在的偏差，确保决策者能够清晰理解。

整合技术、营运和商业性的必要因素，以确定哪些交付创新将具有可扩展的临床和市场影响。

总之，新型药物递送系统正从概念验证的小众技术转变为能够区分治疗方案并影响患者疗效的核心策略资产。先进材料、设备工程和数位健康技术的融合正在拓展标靶递送、缓释性和微创给药的可能性。同时，地缘政治和政策的变化，例如关税调整和区域製造业预期，使得供应链韧性和本地化成为影响成本结构和监管管道的战略要务。

为了充分利用这些趋势，企业必须在产品生命週期的各个阶段都考虑交付因素，优先发展伙伴关係关係以弥补能力缺口，并投资于能够引起支付方和临床医生共鸣的真实世界证据。那些将科学创新与切实可行的商业化计划（确保生产准备就绪、监管预见性和以用户为中心的设计）相结合的企业，更有可能加速产品推广应用，并在医疗服务方面带来可衡量的改进。机会巨大，但要抓住这一机会，研发、营运和商业团队必须协同合作。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 开发用于无痛经皮疫苗和生物相似药递送的微针贴片技术
  • 透过应用人工智慧驱动的预测模型优化基于奈米乳剂的口服药物製剂
  • 采用3D列印技术製造客製化的植入药物释放型装置
  • 用于标靶mRNA和基因治疗的脂质奈米颗粒载体的研究进展
  • 将刺激响应型水凝胶系统整合用于局部和可控的治疗药物释放
  • 新兴的基于外泌体的药物递送平台，可实现精准标靶化和降低毒性
  • 利用新一代干粉吸入系统进行生技药品肺部传递的创新
  • 开发超音波触发的微气泡系统，用于按需特异性药物释放

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 新型药物递送系统市场（依给药途径划分）

  • 吸入
    • 干粉吸入器
    • 喷雾器
  • 注射
    • 肌肉内注射
    • 静脉
    • 皮下
  • 鼻腔
    • 降低
    • 喷
  • 口服
    • 胶囊
    • 液体
    • 药片
  • 经皮
    • 凝胶
    • 修补

9. 新型药物输送系统市场（依技术划分）

  • 水凝胶
    • 自然的
    • 合成
  • 植入
    • 可生物降解
    • 不可生物降解
  • 微型针
    • 涂层
    • 溶解度
    • 中空的
    • 固体的
  • 奈米颗粒
    • 树状聚合物
    • 脂质体
      • 阳离子脂质体
      • 隐形脂质体
    • 聚合物奈米粒子
    • 固体脂质奈米颗粒

第十章：新型药物递送系统市场（依应用领域划分）

  • 心血管系统
    • 支架
    • 经导管装置
  • 内分泌学
    • 糖尿病管理
    • 荷尔蒙补充疗法
  • 感染疾病
    • 抗生素输送
    • 抗病毒药物递送
    • 疫苗接种
  • 神经病学
    • 中枢神经系统疾病
    • 週边疾病
  • 肿瘤学
    • 化疗
    • 免疫疗法
    • 标靶治疗
  • 眼科
    • 眼药水
    • 眼内植入

第十一章 新型药物递送系统市场（依产品类型划分）

  • 缓释注射剂
    • 可生物降解
    • 不可生物降解
  • 药物释放型支架
    • 冠状动脉
    • 邻里
  • 植入式帮浦
    • 点滴帮浦
    • 渗透泵浦
  • 脂质体配方
    • 传统脂质体
    • 隐形脂质体
  • 微针贴片
    • 溶解度
    • 固体的

第十二章：按最终用户分類的新型药物输送系统市场

  • 门诊治疗
  • 诊所
  • 居家医疗
  • 医院
  • 药局

第十三章：按地区分類的新型药物输送系统市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 新型药物递送系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国新型药物传输系统市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Becton, Dickinson and Company
    • Baxter International Inc.
Product Code: MRR-02026C4CB9B9

The Novel Drug Delivery Systems Market is projected to grow by USD 31.13 billion at a CAGR of 9.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.00 billion
Estimated Year [2025] USD 16.40 billion
Forecast Year [2032] USD 31.13 billion
CAGR (%) 9.55%

A comprehensive orientation to how multidisciplinary innovation and patient-centric design are redefining the purpose and opportunity of novel drug delivery platforms

The landscape of drug delivery is undergoing a fundamental redefinition as molecular innovation converges with advanced materials science and patient-centric care models. Novel drug delivery systems encompass a broad array of platforms-from inhalation devices and injectable formats to transdermal patches and cutting-edge micro- and nano-scale carriers-each engineered to enhance therapeutic index, adherence, and targeted biodistribution. This executive summary synthesizes the critical technological, regulatory, and commercial inflection points that are shaping development priorities and investment strategies across biopharma, medtech, and specialty device companies.

Across therapeutic areas, developers are prioritizing delivery as an integral component of drug value rather than a peripheral enabler. This shift is driving more integrated product development lifecycles where formulation scientists, device engineers, and clinical teams co-design solutions to meet complex safety, stability, and usability requirements. Moreover, the growing emphasis on outpatient care and at-home administration is reshaping product specifications and supply chain considerations. As a result, stakeholders who can align scientific innovation with real-world usability and reimbursement pathways will have a decisive advantage in commercializability and patient uptake.

How precision targeting, digital integration, and strategic partnerships are remapping clinical value creation and commercialization pathways in advanced delivery

Several transformative shifts are accelerating the evolution of drug delivery and redefining what success looks like for new therapeutic modalities. First, precision targeting-enabled by nanoparticles, liposomal systems, and implantable devices-has advanced from proof-of-concept to practical clinical application, enabling higher therapeutic concentrations at disease sites while reducing systemic exposure. This technical maturation coincides with regulatory receptivity to combination products and novel excipients, which permits more ambitious formulations and integrated device solutions.

Concurrently, digital health integration is changing the expectations for adherence monitoring and dose personalization. Smart implants, connected infusion pumps, and sensor-integrated patches are moving delivery systems from passive carriers to active participants in care pathways. The commercial landscape is also shifting: strategic partnerships between pharmaceutical firms and specialty device companies are more common, reflecting recognition that complementary expertise is required to navigate complex development, manufacturing, and lifecycle management challenges. Taken together, these dynamics are producing a landscape where cross-functional collaboration, regulatory agility, and supply chain resilience determine which innovations scale into meaningful clinical and commercial outcomes.

Operational and strategic consequences of the United States tariff adjustments in 2025 that reshaped sourcing, manufacturing localization, and supply chain resilience

The tariff environment in the United States in 2025 introduced nuanced operational and strategic pressures across the life sciences supply chain, with variable effects on component sourcing, manufacturing location decisions, and cost structures. Tariff measures targeting specific raw materials and device components increased import costs for certain polymers, specialized lipids, and electronic subsystems used in connected devices. This change prompted an operational reassessment among manufacturers who had previously relied on globalized, cost-optimized sourcing strategies.

In response, many organizations accelerated localization of critical supply chains or established dual-sourcing arrangements to mitigate exposure to tariff volatility. Raising procurement and manufacturing visibility became a priority, as did increased investment in supply chain analytics to model tariff sensitivity across product portfolios. Importantly, these adjustments have implications beyond near-term cost management: decisions to regionalize production, qualify alternative materials, or redesign device architectures are influencing regulatory submission strategies and time-to-market calculations. Companies that proactively integrated tariff scenario planning into their commercialization roadmaps were better positioned to preserve margin and continuity of supply while maintaining development timelines.

Actionable segmentation intelligence linking routes of administration, enabling technologies, therapeutic applications, product typologies, and end-user channels for precise strategic targeting

Segment-level dynamics reveal differentiated opportunities and technical constraints that should inform R&D prioritization and commercial planning. When considering route of administration, inhalation platforms-encompassing dry powder inhalers and nebulizers-are being redeveloped to support biologics and localized pulmonary therapies, while injectable formats, including intramuscular, intravenous, and subcutaneous variants, remain central for systemic biologics and long-acting depot approaches. Nasal delivery through drops and sprays offers a compelling route for rapid CNS and mucosal immunization strategies, and oral delivery across capsules, liquids, and tablets continues to be optimized for stability and patient adherence. Transdermal options, realized through gels and patches, are increasingly attractive for chronic, steady-state therapies and for therapies requiring steady plasma profiles.

From a technology perspective, hydrogels-both natural and synthetic-are maturing as sustained-release matrices, whereas implants, whether biodegradable or nonbiodegradable, support long-duration local therapies and reduced dosing frequency. Microneedles in coated, dissolvable, hollow, and solid formats provide minimally invasive delivery with potential for self-administration, and nanoparticle platforms, including dendrimers, various liposome classes, polymeric nanoparticles, and solid lipid nanoparticles, enable targeted delivery and controlled release. Application-driven segmentation illuminates where clinical need and commercialization potential intersect: cardiovascular interventions that leverage stents and transcatheter devices, endocrinology solutions focused on diabetes management and hormone therapies, infectious disease delivery channels for antibiotics, antivirals, and vaccines, neurology approaches for central and peripheral disorders, oncology delivery systems for chemotherapy, immunotherapy, and targeted agents, and ophthalmology solutions spanning eye drops to ocular implants.

Product-type distinctions further refine go-to-market considerations: depot injections, both biodegradable and nonbiodegradable, offer adherence advantages; drug-eluting stents for coronary and peripheral use require procedural integration; implantable pumps such as infusion and osmotic pumps demand durable power and control solutions; liposomal formulations-standard and stealth variants-affect pharmacokinetics and immunogenicity; and microneedle patches, in dissolvable and solid forms, present unique manufacturing scale-up pathways. Finally, end-user segmentation spanning ambulatory care, clinics, home care, hospitals, and pharmacies defines distribution models, training requirements, and reimbursement touchpoints. Integrating these segmentation lenses enables nuanced product design and market-entry sequencing that align technical feasibility with clinical adoption pathways.

How regional regulatory, reimbursement, and manufacturing landscapes across the Americas, EMEA, and Asia-Pacific influence development priorities and market entry sequencing

Regional dynamics shape prioritization for development, manufacturing, and commercialization of novel delivery systems. In the Americas, innovation clusters in device-enabled biologics and implantable technologies coexist with advanced reimbursement frameworks that can accelerate adoption, but supply chain and tariff considerations necessitate localized manufacturing and regulatory alignment. Europe, Middle East & Africa displays heterogeneity: established regulatory pathways and centralized procurement in some European markets can favor advanced devices and combination products, while emerging markets within the region may prioritize cost-effective, easy-to-administer solutions and decentralized care models. Asia-Pacific presents diverse opportunities driven by large patient populations, expanding clinical trial capacity, and rapid industrial scale-up capabilities, but market entry requires careful navigation of country-specific regulatory nuances and local manufacturing expectations.

These regional contours influence partner selection, clinical development strategies, and commercialization sequencing. For example, companies may prioritize pilot launches in markets with favorable reimbursement policies and strong specialty channel access before expanding into regions where price sensitivity or procurement processes demand alternative value propositions. Similarly, regulatory engagement strategies should reflect regional differences in device and biologic governance, with early dialogue enabling feasibility assessments and pathway optimization. Balancing a global vision with regionalized execution plans is essential to capture adoption momentum while managing operational complexity.

Competitive differentiation driven by integrated technology stacks, strategic collaborations, and a focus on real-world evidence and manufacturing excellence

Competitive dynamics in novel drug delivery systems are characterized by a mix of established pharmaceutical companies, device specialists, and nimble technology innovators. Leading organizations are differentiating through vertically integrated capabilities that span formulation science, device engineering, and manufacturing scale-up, enabling accelerated translation from concept to clinic. Strategic collaborations-ranging from licensing and co-development agreements to equity investments-are common pathways for obtaining complementary competencies, particularly in areas such as nanoparticle engineering, microneedle fabrication, and digital health integration.

Intellectual property remains a central pillar of competitive advantage, as strong patent families around core materials, delivery mechanisms, and device interfaces can create meaningful barriers to entry. However, commercialization success increasingly depends on real-world evidence generation, user-centric design validation, and payer engagement to establish differentiated value. Companies that invest in robust post-market surveillance, adherence analytics, and clinical outcomes studies will be better positioned to defend pricing and expand indications. Manufacturing excellence and regulatory track record are additional differentiators; partners and acquirers favor organizations with demonstrated ability to scale complex biologic formulations, maintain sterility assurance, and navigate combination product submissions efficiently.

Practical and prioritized strategic actions for life sciences leaders to align R&D, supply chain resilience, and commercial evidence generation for sustainable adoption

Industry leaders should adopt a set of prioritized actions to convert technical promise into sustainable commercial outcomes. First, embed delivery strategy early in drug development by co-designing formulations and devices with clinical and regulatory teams, thereby minimizing late-stage redesigns and accelerating approval-readiness. Second, diversify supply chains and qualify alternate materials and vendors to mitigate tariff and geopolitical risks while building redundancy into critical component sourcing. Third, invest in pilot manufacturing and scalable process validation for complex formulations, including liposomal and nanoparticle systems, to reduce time-to-scale when a product advances to pivotal studies.

Additionally, establish strategic partnerships to access complementary capabilities such as microneedle fabrication, implantable device engineering, or digital adherence technologies, and structure agreements to balance risk and upside. Strengthen value demonstration by designing outcomes-based evidence programs that align clinical endpoints with payer requirements and end-user benefits such as reduced hospital visits or improved adherence. Finally, prioritize human factors and training programs to ensure that novel devices and administration routes are intuitive for clinicians and patients, thereby smoothing adoption curves in ambulatory and home-care settings. These integrated actions will improve the likelihood of clinical success and commercial uptake while protecting margin and accelerating patient access.

A reproducible mixed-methods research approach combining rigorous secondary review and expert primary interviews to validate technology readiness and commercial dynamics

This report is grounded in a structured research methodology that blends multi-source secondary analysis with targeted primary inquiry to ensure the findings are robust, actionable, and reproducible. Secondary research included curated reviews of peer-reviewed literature, regulatory guidance documents, patent filings, and technical white papers to map technological trends, regulatory precedents, and materials science advancements. These secondary insights established the foundational taxonomy used to segment routes of administration, enabling technologies, therapeutic applications, product types, and end-user channels.

Primary research involved in-depth interviews with cross-functional stakeholders, including formulation scientists, device engineers, regulatory affairs specialists, clinical investigators, manufacturing leaders, and commercial executives. These conversations validated technical feasibility assessments, surfaced practical barriers to adoption, and clarified procurement and reimbursement dynamics across regions. Quantitative validation checks were performed through triangulation of interview inputs against secondary sources and technology readiness indicators. Finally, internal subject-matter experts synthesized the evidence into scenario analyses and strategic recommendations, with iterative review cycles to address potential bias and ensure clarity for decision-makers.

Synthesis of technological, operational, and commercial imperatives that will determine which delivery innovations translate into scalable clinical and market impact

In conclusion, novel drug delivery systems are transitioning from niche technical demonstrations to core strategic assets that determine therapeutic differentiation and patient outcomes. The convergence of advanced materials, device engineering, and digital health capabilities is expanding what is possible in targeted delivery, sustained release, and minimally invasive administration. At the same time, geopolitical and policy shifts, including tariff changes and regional manufacturing expectations, have made supply chain resilience and localization strategic imperatives that influence both cost structures and regulatory pathways.

To capture the full upside of these trends, organizations must integrate delivery considerations across the product lifecycle, prioritize partnerships to fill capability gaps, and invest in real-world evidence that resonates with payers and clinicians. Those who align scientific ingenuity with pragmatic commercialization planning-ensuring manufacturing readiness, regulatory foresight, and user-centric design-will accelerate adoption and deliver measurable improvements in care. The opportunities are significant, but realizing them requires coordinated action across R&D, operations, and commercial functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of microneedle patch technology for pain-free transdermal vaccine and biosimilar delivery
  • 5.2. Application of AI-driven predictive modeling to optimize nanoemulsion-based oral drug formulation
  • 5.3. Adoption of 3D printing technologies for customized implantable drug-eluting device fabrication
  • 5.4. Advancements in lipid nanoparticle carriers for targeted mRNA and gene therapy applications
  • 5.5. Integration of stimuli-responsive hydrogel systems for localized and controlled therapeutic release
  • 5.6. Emergence of exosome-based drug delivery platforms for precision targeting and reduced toxicity
  • 5.7. Innovations in pulmonary delivery of biologics using next-generation dry powder inhaler systems
  • 5.8. Development of ultrasound-triggered microbubble systems for on-demand site-specific drug release

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Novel Drug Delivery Systems Market, by Route Of Administration

  • 8.1. Inhalation
    • 8.1.1. Dry Powder Inhalers
    • 8.1.2. Nebulizers
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Nasal
    • 8.3.1. Drops
    • 8.3.2. Sprays
  • 8.4. Oral
    • 8.4.1. Capsules
    • 8.4.2. Liquids
    • 8.4.3. Tablets
  • 8.5. Transdermal
    • 8.5.1. Gels
    • 8.5.2. Patches

9. Novel Drug Delivery Systems Market, by Technology

  • 9.1. Hydrogels
    • 9.1.1. Natural
    • 9.1.2. Synthetic
  • 9.2. Implants
    • 9.2.1. Biodegradable
    • 9.2.2. Nonbiodegradable
  • 9.3. Microneedles
    • 9.3.1. Coated
    • 9.3.2. Dissolvable
    • 9.3.3. Hollow
    • 9.3.4. Solid
  • 9.4. Nanoparticles
    • 9.4.1. Dendrimers
    • 9.4.2. Liposomes
      • 9.4.2.1. Cationic Liposomes
      • 9.4.2.2. Stealth Liposomes
    • 9.4.3. Polymeric Nanoparticles
    • 9.4.4. Solid Lipid Nanoparticles

10. Novel Drug Delivery Systems Market, by Application

  • 10.1. Cardiovascular
    • 10.1.1. Stents
    • 10.1.2. Transcatheter Devices
  • 10.2. Endocrinology
    • 10.2.1. Diabetes Management
    • 10.2.2. Hormone Replacement
  • 10.3. Infectious Diseases
    • 10.3.1. Antibiotic Delivery
    • 10.3.2. Antiviral Delivery
    • 10.3.3. Vaccine Delivery
  • 10.4. Neurology
    • 10.4.1. CNS Disorders
    • 10.4.2. Peripheral Disorders
  • 10.5. Oncology
    • 10.5.1. Chemotherapy
    • 10.5.2. Immunotherapy
    • 10.5.3. Targeted Therapy
  • 10.6. Ophthalmology
    • 10.6.1. Eye Drops
    • 10.6.2. Ocular Implants

11. Novel Drug Delivery Systems Market, by Product Type

  • 11.1. Depot Injections
    • 11.1.1. Biodegradable
    • 11.1.2. Nonbiodegradable
  • 11.2. DrugEluting Stents
    • 11.2.1. Coronary
    • 11.2.2. Peripheral
  • 11.3. Implantable Pumps
    • 11.3.1. Infusion Pumps
    • 11.3.2. Osmotic Pumps
  • 11.4. Liposomal Formulations
    • 11.4.1. Conventional Liposomes
    • 11.4.2. Stealth Liposomes
  • 11.5. Microneedle Patches
    • 11.5.1. Dissolvable
    • 11.5.2. Solid

12. Novel Drug Delivery Systems Market, by End User

  • 12.1. Ambulatory Care
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
  • 12.5. Pharmacies

13. Novel Drug Delivery Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Novel Drug Delivery Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Novel Drug Delivery Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Pfizer Inc.
    • 16.3.3. Novartis AG
    • 16.3.4. F. Hoffmann-La Roche Ltd.
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Sanofi S.A.
    • 16.3.7. GlaxoSmithKline plc
    • 16.3.8. AstraZeneca PLC
    • 16.3.9. Becton, Dickinson and Company
    • 16.3.10. Baxter International Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCI